128 related articles for article (PubMed ID: 22302442)
1. Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint.
Hong S; Shi L
Stat Med; 2012 Apr; 31(9):831-43. PubMed ID: 22302442
[TBL] [Abstract][Full Text] [Related]
2. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
3. Analysis of tumor burden versus progression-free survival for Phase II decision making.
Fridlyand J; Kaiser LD; Fyfe G
Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
[TBL] [Abstract][Full Text] [Related]
4. Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?
Carroll KJ
J Biopharm Stat; 2013; 23(5):1188-200. PubMed ID: 23957523
[TBL] [Abstract][Full Text] [Related]
5. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
Nikolakopoulos S; van der Wal WM; Roes KC
J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
[TBL] [Abstract][Full Text] [Related]
6. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma.
Louvet C; de Gramont A; Tournigand C; Artru P; Maindrault-Goebel F; Krulik M
Cancer; 2001 Jun; 91(11):2033-8. PubMed ID: 11391582
[TBL] [Abstract][Full Text] [Related]
7. Joint probability of statistical success of multiple phase III trials.
Zhang J; Zhang JJ
Pharm Stat; 2013; 12(6):358-65. PubMed ID: 24106067
[TBL] [Abstract][Full Text] [Related]
8. The use of phase 2 interim analysis to expedite drug development decisions.
Huang J; Das A; Burger HU; Zhong W; Zhang W; Lieberman G
Contemp Clin Trials; 2014 Jul; 38(2):235-44. PubMed ID: 24854415
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.
Nickolich M; Babakoohi S; Fu P; Dowlati A
Clin Lung Cancer; 2014 May; 15(3):207-12. PubMed ID: 24485231
[TBL] [Abstract][Full Text] [Related]
10. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
11. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of early efficacy endpoints for proof-of-concept trials.
Chen C; Sun L; Li CL
J Biopharm Stat; 2013 Mar; 23(2):413-24. PubMed ID: 23437947
[TBL] [Abstract][Full Text] [Related]
13. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG; Tian C; Bookman MA
Gynecol Oncol; 2010 May; 117(2):324-9. PubMed ID: 20185168
[TBL] [Abstract][Full Text] [Related]
14. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
Huang B; Talukder E; Han L; Kuan PF
J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
[TBL] [Abstract][Full Text] [Related]
15. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
16. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
17. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
18. Tumor burden modeling versus progression-free survival for phase II decision making.
Kaiser LD
Clin Cancer Res; 2013 Jan; 19(2):314-9. PubMed ID: 23172885
[TBL] [Abstract][Full Text] [Related]
19. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
20. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
Nomura S; Hirakawa A; Hamada C
J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
